Haemonetics Corporation
Haemonetics Corporation Fundamental Analysis
Haemonetics Corporation (HAE) shows moderate financial fundamentals with a PE ratio of 16.42, profit margin of 13.31%, and ROE of 20.26%. The company generates $1.3B in annual revenue with moderate year-over-year growth of 3.95%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 59.1/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze HAE's fundamental strength across five key dimensions:
Efficiency Score
WeakHAE struggles to generate sufficient returns from assets.
Valuation Score
ModerateHAE shows balanced valuation metrics.
Growth Score
ModerateHAE shows steady but slowing expansion.
Financial Health Score
ModerateHAE shows balanced financial health with some risks.
Profitability Score
ModerateHAE maintains healthy but balanced margins.
Key Financial Metrics
Is HAE Expensive or Cheap?
P/E Ratio
HAE trades at 16.42 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, HAE's PEG of 2.69 indicates potential overvaluation.
Price to Book
The market values Haemonetics Corporation at 3.16 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 5.38 times EBITDA. This is generally considered low.
How Well Does HAE Make Money?
Net Profit Margin
For every $100 in sales, Haemonetics Corporation keeps $13.31 as profit after all expenses.
Operating Margin
Core operations generate 19.21 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $20.26 in profit for every $100 of shareholder equity.
ROA
Haemonetics Corporation generates $7.04 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Haemonetics Corporation generates strong operating cash flow of $338.96M, reflecting robust business health.
Free Cash Flow
Haemonetics Corporation generates strong free cash flow of $308.19M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $6.58 in free cash annually.
FCF Yield
HAE converts 10.67% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
16.42
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
2.69
vs 25 benchmark
P/B Ratio
Price to book value ratio
3.16
vs 25 benchmark
P/S Ratio
Price to sales ratio
2.19
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
1.34
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.75
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.20
vs 25 benchmark
ROA
Return on assets percentage
0.07
vs 25 benchmark
ROCE
Return on capital employed
0.13
vs 25 benchmark
How HAE Stacks Against Its Sector Peers
| Metric | HAE Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 16.42 | 29.43 | Better (Cheaper) |
| ROE | 20.26% | 800.00% | Weak |
| Net Margin | 13.31% | -20145.00% (disorted) | Strong |
| Debt/Equity | 1.34 | 0.30 | Weak (High Leverage) |
| Current Ratio | 1.75 | 4.64 | Neutral |
| ROA | 7.04% | -17936.00% (disorted) | Weak |
HAE outperforms its industry in 2 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Haemonetics Corporation's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
38.66%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
120.69%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
15.68%
Industry Style: Defensive, Growth, Innovation
High Growth